FDA reorganizes cancer drug division; Seattle Genetics, Oxford Biotherapeutics to collaborate on antibody-drug conjugates;

@FierceBiotech: Novartis hasn't cut R&D spend, unlike some drugmakers. Has logged 17 new drug approvals over the past 1.5 years in U.S., Europe | Follow @FierceBiotech

@JohnCFierce: Dutch biotech AM-Pharma raises €29.2 million in D round. Report | Follow @JohnCFierce

@RyanMFierce: Kiwi firm (not fruit) Biomatters, which sells scientific software, has opened its first U.S. offices in NJ and CA. Item | Follow @RyanMFierce

@MaureenFierce: Pharma hiring on the rise for the fourth quarter in a row. Story | Follow @MaureenFierce

> The FDA has reorganized its oncology division. The Center for Drug Evaluation and Research's Office of Oncology Drug Products has been reorganized and renamed the Office of Hematology and Oncology Products. "Under the new office structure, the agency anticipates greater clarity and more transparent interactions with companies about the requirements to bring cancer treatments to market," said CDER director Dr. Janet Woodcock. "We don't expect these changes to slow down pending applications, in fact, we expect to see greater efficiencies that will better support our work to get cancer treatments to patients." Dr. Richard Pazdur will continue to serve as the office director. FDA release

> Seattle Genetics and Oxford Biotherapeutics plan to collaborate on new antibody-drug conjugates for cancer. Release

> Merck and BGI have forged a collaboration to focus on the discovery and development of biomarkers and genomic technologies. Release

> Oncothyreon has licensed in a preclinical pan-inhibitor of the Bcl-2 family of anti-apoptotic proteins from Sanford-Burnham. Release

> Supergen has adopted the new name of Astex Pharmaceuticals following its acquisition of the U.K. biotech. The company's stock ticker is changing to ASTX. Report

Pharma News

> For most Americans, new drugs equal better drugs. Article

> Ex-Genzyme chief's $10M gift kicks off MGH cancer center. Report

> U.K. watchdog may turn to social media for side-effect reports. News

> Victoza data supports early use as GLP debate looms. Story

> Novartis aims to beat $1.9B in cost savings by year's end. Report

Biotech Research News

> From a poisonous crocus, comes an anti-cancer smart bomb. News

> Drugs in search of LTR with right protein. Report

> New obesity drugs will tell the brain that enough is enough. Article 

> Green-glowing cats light the way to possible new AIDS treatment. News

> Embryonic, induced pluripotent stem cells found to be similar. Report 

Manufacturing News

> Survey: Pharma hiring on the rise. Story

> iPad can be lean enabler in hands of execs. Article

> Patheon reveals strategy amid poor financials. Report 

> German trial a step toward upcoming track/trace mandate. News

> Roche tops DJ healthcare sustainability index. Story

And Finally... The number of diabetics around the world has soared to 366 million, presenting health systems with an enormous--and rapidly growing--challenge. Story

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.